Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339896 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL15898923 | 0.86 | CFTR (0.49) | MAPTKDM4EHSD17B10HPGDTSHR | |
| SCHEMBL16563455 | 0.84 | ALDH1A1 (0.49) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL30935665 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL3073456 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL13139917 | 0.82 | CA12 (0.50) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL24369481 | 0.81 | HTT (0.53) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL3074755 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL3077982 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL3078049 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | NEURO3 THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025029897-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | NEURO3 THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | QDPR, DPYD, P2RX4 | SMN1; SMN2 2376/4885MAPT 3582/4885NPC1 1633/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | SMN1; SMN2 3214/4885MAPT 2560/4885NPC1 3271/4885 |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | SMN1; SMN2 3045/4885MAPT 2064/4885NPC1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.